Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | BMP1 | P13497 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894244 | 0.91 | TRPA1 (0.56) | TRPA1ALDH1A1KMT2APTGER1MMP3 | |
| SCHEMBL16894086 | 0.90 | ALDH1A1 (0.65) | TRPA1ALDH1A1KMT2APTGER1RORC | |
| SCHEMBL16894092 | 0.90 | ALDH1A1 (0.59) | TRPA1ALDH1A1KMT2APTGER1MMP3 | |
| SCHEMBL16894155 | 0.90 | ALDH1A1 (0.56) | TRPA1ALDH1A1KMT2APTGER1MMP3 | |
| SCHEMBL16906522 | 0.88 | ALDH1A1 (0.63) | TRPA1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL16894115 | 0.87 | TDP1 (0.55) | TRPA1ALDH1A1KMT2APTGER1RORC | |
| SCHEMBL16894100 | 0.87 | TRPA1 (0.54) | TRPA1ALDH1A1KMT2APTGER1MMP3 | |
| SCHEMBL16894225 | 0.87 | TRPA1 (0.53) | TRPA1ALDH1A1KMT2APTGER1MMP3 | |
| SCHEMBL16894169 | 0.86 | ALDH1A1 (0.53) | TRPA1ALDH1A1KMT2APTGER1BMP1 | |
| SCHEMBL16894081 | 0.85 | TRPA1 (0.61) | TRPA1ALDH1A1PTGER1MMP3RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | claimed |
| EP-2900642-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | claimed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | claimed |
| EP-2900642-B1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| EP-2900642-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | TRPA1, TRPV1, TRPV5 | TRPA1 1/4885ALDH1A1 949/4885KMT2A 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.